Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, will share new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The company will present data demonstrating that its next-generation suppressor tRNAs (sup-tRNAs) restore full‑length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). The company will also present data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model as well as functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM‑TTNtv).
Key takeaways from the presentation include Tevard’s next‑generation suppressor tRNAs achieving approximately 100% restoration of full‑length dystrophin in DMD models and delivering durable full‑length titin rescue in TTN‑related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.
These data represent significant progress for patients with DMD and DCM‑TTNtv, who currently have limited treatment options. DMD is a severe muscle-wasting disease caused by mutations in the dystrophin gene, while DCM‑TTNtv is a leading genetic cause of dilated cardiomyopathy. The ability to restore full-length proteins using suppressor tRNAs could offer a transformative approach for these and other genetic disorders caused by nonsense mutations.
For more information, visit www.tevard.com.
